RZLT Stock — Rezolute Inc

Rezolute Inc (RZLT)

Updated October 16, 2026.

RZLT is a Stock. Total return is 468.3% over the past 14.4 years, 149.8 points behind SPY at 618.1%.

Rezolute is a late-stage rare disease company developing ersodetug, a monoclonal antibody treatment for congenital hyperinsulinism and other hypoglycemia conditions, with its lead program currently in Phase 3 clinical trials. The company does not currently distribute dividends. Rezolute appeals primarily to investors seeking exposure to clinical-stage biopharmaceutical development rather than those seeking income.

RZLT performance versus SPY

Price and return data through 2026-10-16.

Total return is 468.3% over the past 14.4 years, 149.8 points behind SPY at 618.1%. Over the past year its total return — price change plus distributions reinvested — is -59.6%. Its deepest 1-year drawdown was 87.2%.

RZLT key facts

Asset type

Stock

Asset class

Equity

Inception date

05/08/2012

Distribution frequency

None

Last close

$3.58 (as of 2026-10-16)

Market cap

$346,265,952

Average volume

1397886.0

Payment date

10/13/2020

Beta

0.542

Payout ratio

0.0%

EPS

$-0.75

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

RZLT risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 87.2%.

Who may consider RZLT — and who may not

It is a weaker fit for investors who need monthly cash flow (RZLT does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on RZLT

• All tickers starting with R

Tagged: Healthcare.

Frequently asked questions